Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Subjects Considered Likely to Respond to CB-03-10: early-phase trial registry
1 of 1 indexed Subjects Considered Likely to Respond to CB-03-10 trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #11,370 of 28,707 conditions by registered trial count.
1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count
Subjects Considered Likely to Respond to CB-03-10: 1 US clinical trial tracked, 1 recruiting.
Subjects Considered Likely to Respond to CB-03-10 is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Cosmo Technologies, running 1 of these trials.
Enrollment posture brief
Registry condition subjects-considered-likely-to-respond-to-cb-03-10
OPEN 1 | RECR 100% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Subjects Considered Likely to Respond to CB-03-10 lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Subjects Considered Likely to Respond to CB-03-10 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Subjects Considered Likely to Respond to CB-03-10 is recruiting above its size-band peers.
1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
1 total, page 1 of 1
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Subjects Considered Likely to Respond to CB-03-10 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Subjects Considered Likely to Respond to CB-03-10 trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Subjects Considered Likely to Respond to CB-03-10 page
1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Subjects Considered Likely to Respond to CB-03-10 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Cosmo Technologies sponsors the most Subjects Considered Likely to Respond to CB-03-10 trials on record, review their full trial history before evaluating a specific study. See Cosmo Technologies's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Subjects Considered Likely to Respond to CB-03-10 condition card totals 1 registered trials; most-linked intervention CB-03-10; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.